Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.
|Number of pages
|JNCCN Journal of the National Comprehensive Cancer Network
|Published - Sep 1 2015
ASJC Scopus subject areas